Browsing by Author "Özcan, A"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    The serum zinc and copper values of the Morkaraman and Tuj sheep grown up in the pasture conditions in and around Kars
    Kaya, N; Utlu, N; Uyanik, BS; Özcan, A
    This study was performed on 100 sheep, of which SO were Morkaraman and SO were Tuj, grown up in the pasture conditions in and around Kars. The serum zinc and copper values of the animals were analysed with Atomic Absorbtion Spectrophotometre. The serum zinc and copper values were respectively determined as; 40.56 +/- 5.6 mu g/dl, 80.10 +/- 7.49 mu g/dl in Morkaramans and, 38.72 +/- 5.32 mu g/dl, 75.04 +/- 6.58 mu g/dl in Tujs. There were no significant differences between the value of zinc and copper statistically.
  • No Thumbnail Available
    Item
    Patient and physician delay in the diagnosis and treatment of non-small cell lung cancer in Turkey
    Yurdakul, AS; Kocatürk, C; Bayiz, H; Gürsoy, S; Bircan, A; Özcan, A; Akkoçlu, A; Uluorman, F; Çelik, P; Köksal, D; Ulubas, B; Sercan, E; Özbudak, Ö; Göksel, T; Önalan, T; Yamansavci, E; Türk, F; Yuncu, G; Çopuraslan, Ç; Mardal, T; Tuncay, E; Karamustafaoglu, A; Yildiz, P; Seçik, F; Kaplan, M; Çaglar, E; Ortaköylü, M; Önal, M; Turna, A; Hekimoglu, E; Dalar, L; Altin, S; Gülhan, M; Akpinar, E; Savas, I; Firat, N; Çamsari, G; Özkan, G; Çetinkaya, E; Kamiloglu, E; Çelik, B; Havlucu, Y
    Aim: The early diagnosis and treatment of lung cancer are important for the prognosis of patients with lung cancer. This study was undertaken to investigate patient and doctor delays in the diagnosis and treatment of NSCLC and the factors affecting these delays. Materials and methods: A total of 1016 patients, including 926 (91.1%) males and 90 (8.9%) females with a mean age of 61.5 +/- 10.1 years, were enrolled prospectively in this study between May 2010 and May 2011 from 17 sites in various Turkish provinces. Results: The patient delay was found to be 49.9 +/- 96.9 days, doctor delay was found to be 87.7 +/- 99.6 days, and total delay was found to be 131.3 +/- 135.2 days. The referral delay was found to be 61.6 +/- 127.2 days, diagnostic delay was found to be 20.4 +/- 44.5 days, and treatment delay was found to be 24.4 +/- 54.9 days. When the major factors responsible for these delays were examined, patient delay was found to be more frequent in workers, while referral delay was found to be more frequent in patients living in villages (p < 0.05). We determined that referral delay, doctor delay, and total delay increased as the number of doctors who were consulted by patients increased (p < 0.05). Additionally, we determined that diagnostic and treatment delays were more frequent at the early tumour stages in NSCLC patients (p < 0.05). Discussion: The extended length of patient delay underscores the necessity of educating people about lung cancer. To decrease doctor delay, education is a crucial first step. Additionally, to further reduce the diagnostic and treatment delays of chest specialists, multidisciplinary management and algorithms must be used regularly. (C) 2015 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Patient and doctor delays in the diagnosis and treatment of non-small cell lung cancer in Turkey
    Yurdakul, A; Kocatürk, C; Bayiz, H; Gürsoy, S; Bircan, A; Özcan, A; Akkoçlu, A; Uluorman, F; Çelik, P; Köksal, D; Ulubas, B; Sercan, E; Özbudak, Ö; Göksel, T; Önalan, T; Yamansavci, E; Türk, F; Yuncu, G; Çopuraslan, Ç; Mardal, T; Tuncay, E; Karamustafaoglu, A; Yildiz, P; Seçik, F; Kaplan, M; Çaglar, E; Ortaköylü, M; Önal, M; Turna, A; Hekimoglu, E; Dalar, L; Altin, S; Gülhan, M; Akpinar, E; Savas, I; Firat, N; Çamsari, G; Özkan, G; Çetinkaya, E; Kamiloglu, E; Çelik, B; Havlucu, Y
  • No Thumbnail Available
    Item
    Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
    Koç, S; Sen, S; Terzi, Y; Kizilay, F; Demir, S; Aksoy, DB; Kurtulus, F; Bilge, N; Idilman, E; Uzunköprü, C; Güngör, S; Çilingir, V; Ethemoglu,Ö; Boz, C; Gümüs, H; Kiliç, AK; Kisabay, A; Bir, LS; Turan, ÖF; Soysal, A; Köseoglu, M; Uzuner, GT; Bayindir, H; Kabay, SC; Çam, M; Yayla, V; Tan, HY; Özcan, A; Taskapioglu,Ö; Korkmaz, M; Tamam, Y; Inanç, Y; Efendi, H; Kotan, D; Yetkin, MF; Bilgiç, AB; Saçmaci, H; Demirci, S; Çelik, Y; Poyraz, T; Terzi, M
    Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz May & imath;s University's Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.